THC Global Group (ASX: THC) has partnered with Malaysian agri-tech company Heleogenics to advance their ‘Asian Markets Strategy’ for Asia and the Middle East.
The partnership will start by working with the Malaysian Government towards the legalisation of medicinal cannabis, including the development of policy and legislation.
Heleogenics is associated with Sengenics, a global medical bio-tech company primarily focussed on the study of proteins for medical diagnostics and the development of novel therapies.
THC’s ‘Asian Markets Strategy’ is focussed on entering into commercial partnerships with leaders within specific complimentary industries.
CEO of THC Global Ken Charteris said, “Working with the Heleogenics team, who are leaders in the bio-tech and agri-tech sector within Asia brings a significant wealth of experience both within government liaison in addition to broadening the Company’s research and development capabilities.
“In securing commercial partnerships with established businesses like Heleogenics within Asia, we are able to enter markets in an accelerated manner as soon as legislative changes are made, ensuring a first-to-market approach with significantly lower capital outlay than operating solely.”
Executive Director of Heleogenics Dr Arif Anwar said, “We are pleased to be working closely with THC Global towards delivering medicinal cannabis in the Asian region in the near term, as well as working on research and development within the sector, leveraging THC Global’s experience in plant breeding and cultivation for medical use.”